Sat, Jan 31, 2015, 9:13 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Roche Holding AG Message Board

sy3dney 1495 posts  |  Last Activity: Aug 14, 2013 12:31 PM Member since: Aug 31, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The Wedbush presentation is going to be
    broadcast in about 15 min --
    go to the IMGN website

    Just a reminder for today.

  • Needham raised their TP from $20 to $28
    in a report.

  • Reply to

    Volume gets jacked up after the close !!

    by sy3dney Jun 21, 2013 4:49 PM
    sy3dney sy3dney Jun 21, 2013 7:37 PM Flag

    Well now we have agreement at 7:30ET
    Both sources are at 1,226K and that makes about 450k in the after hours.
    Interesting, but I dk the option effect because it might be to soon.

  • It looks like some stock swaps going on --
    The vol at about the close on Yahoo was at about 779K -- then
    at roughly 1/2 hr after the close it was at 1,134K on Yahoo.
    And over on ETrade it had jumped to 1,215K -- now it's been
    reduced back to 949K ! Double counting on a swap isn't unheard of.
    We'll probably know after watching a few more days.
    Good weekend everyone!!
    Jon

  • Anyone listen ?? It was supposed to be broadcast around 9:20PST.
    TIA

  • 6 meetings before the e/o the month to pay attention to ---
    6/11 Vontobel Summer Conference in Switzerland -- Roche there.
    6/13 Goldman Sachs 34th Annual Global Healthcare Conference -- Roche there.
    6/18 Union Investment/DVFA, Innovative Strategies in the Life Sciences Sector
    Frankfurt, Germany -- Roche there.
    6/20 Barclays Capital, International Franchise Conference in Napa CA --
    Roche there.
    6/24 JP Morgan, European Healthcare Conference in London UK -- Roche there.
    6/26-28 Bioconjugates Conference in San Diego -- both IMGN and Roche there.
    6/27 8:30am Bob Lutz/ 11:15am Hans Erickson both of IMGN.

    GLTA -- Jon

    Sentiment: Strong Buy

  • With all of the AACR presentations it'll be
    a nice BOOST for the industry IMO.

    The address is posted over on IV #35899

    GLTA

  • The date on the report is 3/30/13.

    S&P rates it 5 stars with a Strong Buy.

    It has a 12 month price target of $17.00

    Sentiment: Strong Buy

  • Reply to

    One surprise in the FDA news

    by sy3dney Feb 22, 2013 1:19 PM
    sy3dney sy3dney Feb 22, 2013 1:28 PM Flag

    "This was not a major surprise, since EMILIA included about 12% front-line mBC patients (about 60 1st-line mBC patients in the T-DM1 arm of the EMILIA trial), but it was definitely not a given."

  • Reply to

    One surprise in the FDA news

    by sy3dney Feb 22, 2013 1:19 PM
    sy3dney sy3dney Feb 22, 2013 1:21 PM Flag

    "The biggest news in today's press release, given that approval was expected, was that the label allows for use in front-line HER-2 positive metastatic breast cancer," says Cowen's Simos Simeonidis in a note this This morning -- "This was not a major surprise, since EMILIA included about 12% front-line mBC patients (about 60 1st-line mBC patients in the T-DM1 arm of the EMILIA trial), but it was definitely not a given."

  • "The biggest news in today's press release, given that approval was expected, was that the label allows for "The biggest news in today's press release, given that approval was expected, was that the label allows for use in front-line HER-2 positive metastatic breast cancer," says Cowen's Simos Simeonidis in a note.

    Sentiment: Strong Buy

  • Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Postive Metastatic Breast Cancer

    Abstract

    Purpose Trastuzumab emtansine (T-DM1), an antibody-drug conjugate composed of the cytotoxic agent DM1 conjugated to trastuzumab via a stable thioether linker, has shown clinical activity in single-arm studies enrolling patients with human epidermal growth factor receptor 2 (HER2) –positive metastatic breast cancer (MBC) whose disease had progressed on HER2-targeted therapy in the metastatic setting.

    Patients And Methods Patients (N = 137) with HER2-positive MBC or recurrent locally advanced breast cancer were randomly assigned to trastuzumab plus docetaxel (HT; n = 70) or T-DM1 (n = 67) as first-line treatment until disease progression or unacceptable toxicity. Primary end points were investigator-assessed progression-free survival (PFS) and safety. Key secondary end points included overall survival (OS), objective response rate (ORR), duration of objective response, clinical benefit rate, and quality of life.

    Results Median PFS was 9.2 months with HT and 14.2 months with T-DM1 (hazard ratio, 0.59; 95% CI, 0.36 to 0.97); median follow-up was approximately 14 months in both arms. ORR was 58.0% (95% CI, 45.5% to 69.2%) with HT and 64.2% (95% CI, 51.8% to 74.8%) with T-DM1. T-DM1 had a favorable safety profile versus HT, with fewer grade ≥ 3 adverse events (AEs; 46.4% v 90.9%), AEs leading to treatment discontinuations (7.2% v 40.9%), and serious AEs (20.3% v 25.8%). Preliminary OS results were similar between treatment arms; median follow-up was approximately 23 months in both arms.

    Conclusion In this randomized phase II study, first-line treatment with T-DM1 for patients with HER2-positive MBC provided a significant improvement in PFS, with a favorable safety profile, versus HT.

    Sentiment: Strong Buy

  • Interesting to see the stocks direction --
    : )

    Sentiment: Strong Buy

  • sy3dney sy3dney Jan 29, 2013 3:28 PM Flag

    Thanks to Stokpoor over on IV msg# 35041

  • sy3dney sy3dney Jan 29, 2013 3:02 PM Flag

    More to the story --
    The EMILIA trial had progression free survival (PFS) as one of its primary endpoints, and patients who received T-DM1 experienced a 35 percent reduction in the risk of their disease worsening or death compared to those who received lapatinib plus capecitabine. The median PFS improved by 3.2 months from 6.4 months of lapatinib and capecitabine to 9.6 months of T-DM1 (hazard ratio=0.65; p

    Sentiment: Strong Buy

  • January 29, 2013 (Tokyo) – Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama (hereafter, "Chugai")] announced today that it has filed a new drug application to the Ministry of Health, Labour and Welfare (MHLW), for antibody-drug conjugate "trastuzumab emtansine (T-DM1)" for the treatment of "HER2-positive metastatic or recurrent breast cancer."

    Chugai filed the application with the MHLW based on the results from an overseas phase III clinical trial (the EMILIA trial) and a domestic phase II clinical trial.

    The EMILIA trial is an international phase III study comparing T-DM1 alone to lapatinib in combination with capecitabine in people with HER2-positive metastatic or unresectable locally advanced breast cancer who had previously been treated with trastuzumab and a taxane chemotherapy. Japanese patients were not included in the EMILIA trial.

    The EMILIA trial had progression free survival (PFS) as one of its primary endpoints, and patients who received T-DM1 experienced a 35 percent reduction in the risk of their disease worsening or death compared to those who received lapatinib plus capecitabine. The median PFS improved by 3.2 months from 6.4 months of lapatinib and capecitabine to 9.6 months of T-DM1 (hazard ratio=0.65; p

    Sentiment: Strong Buy

  • Rumor has it that at least 2 brokers said something today
    that they like IMGN better than before.
    Regards and I guess we'll have to dig around to find anything.
    GLTA

    Sentiment: Strong Buy

  • I had written over early Dec a LOT of calls due in Feb
    including the 14 and 15s. Now I have NO written calls!
    First time in quite a while.
    Over the next 4 weeks the movement should be very interesting.
    HIGHER IMO ---
    : )

    Sentiment: Strong Buy

  • Reply to

    The Pipeline Page was just updated last Friday

    by sy3dney Dec 24, 2012 5:23 PM
    sy3dney sy3dney Dec 26, 2012 1:15 PM Flag

    The individual pages called N901 and
    Other Compounds are the pages that were changed.
    They both have the update dates on the lower right.

    As to what was changed I DK.

    GLTA

    Sentiment: Strong Buy

  • Anyone see anything added or changed??
    TIA
    Have a HAPPY !!

    Sentiment: Strong Buy

RHHBY
33.76-0.62(-1.79%)Jan 30 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.